Patients during their moderate to severe stage of diseases often ask: “Is there a cure?” or “Will I get better with or without treatment?” – in their hopes of seeking answers. However, after knowing that they have an incurable terminal disease, they are shunned.
While the healthcare sector has advanced enough to provide treatments to alleviate symptoms temporarily, the tragic course of the disease’s progression without an end cannot be reversed.
Unfortunately, there are several diseases that still lack medical treatment to stop their course. Even if therapy is made available to treat these diseases, some of the patients end up developing distressing symptoms.
Identifying the matter, 4P-Pharma is a clinical-stage company dedicated to regenerate active drugs to develop first-in-class therapies to cure untreated serious diseases.
Revital Rattenbaach, the CEO of the company, shares the journey behind the success of the company.
Below are the details of the interview.
Please brief us about the organization and its inception.
4P-Pharma is clinical-stage Biotech specializing in drug regeneration for treating serious diseases with no existing treatment. Sourcing innovations from top academics, 4P-Pharma launches a single product vehicle (SPV) once programs are ready for First in Human studies. Our first SPV, 4Living Biotech, has initiated a Phase 2b trial on a CXCR4 antagonist for treating acute and chronic pulmonary complications to viral infections.
How is advancing technology in the field helping the growth of the organization?
As a flagship program of 4P-Pharma, the advancement of 4Living Biotech’s technology—from an academic concept to a clinical stage SPV—exemplifies the robustness and tremendous potential of the 4P-Pharma strategy to regenerate existing drugs to treat serious diseases with no existing treatment. Through 4Living Biotech, 4P-Pharma has assembled a proprietary circular-based development engine enabling us to link drug mechanisms of action and disease biology, broadening therapeutic scope to unmet needs.
The spread of infectious diseases has increased, especially post-pandemic. How is your organization breaking this chain and ensuring individual and societal health?
Recent pandemic spread has demonstrated the central role of co-morbidities—such as diabetes, obesity, or age—which have enlightened the limitation of pure prophylactic approaches and the need to offer curative solutions for ICU patients. By linking drug mechanisms of action and disease biology, 4P-Pharma intends to develop disease modifiers and regenerated drugs to complement the current prophylactic arsenal and bring a positive contribution to the ICU critical stage to save lives.
What are the key products and services that the organization is providing and how is it impacting the demographic concerned?
4P-Pharma’s key product is an immune stimulant, which intends to boost the fragile immune systems of patients suffering from co-morbidities. Leveraging a drug regeneration strategy, 4P-Pharma facilitates worldwide access to novel curative solutions for all ICU patients through its SPV – 4Living Biotech.
Highlighting the importance of preventive care, how has your organization spread awareness regarding this, and what has been its impact so far?
Most of the solutions that are explored are prophylactic with vaccines or anti-viral treatments that are specific to the virus itself. We propose a complementary solution targeting an individual’s immune system response independent of the infection type. Despite the existence of vaccines for influenza or for COVID-19, there are still millions of patients hospitalized for those respiratory infectious diseases.
People with a lack of resources are most susceptible to infections. How is your organization helping provide this section with infection-free, healthy lives?
The COVID-19 pandemic had a huge economic impact all over the world, partially due to the recurrent lock-up periods that were necessary to protect the lives of the most fragile population. A curative solution would have probably avoided those lock-ups.
As a guiding light, could you please enlighten us on how you turned the challenges into opportunities?
The last pandemic has illustrated the exponential exposure of people suffering from co-morbidities and the need to complement the prophylactic arsenal with complementary curative solutions for extreme situations like ICU. In addition, the dynamic of the pandemic emphasized the need to be agile and highly responsive where novel drug development strategies could emerge. By focusing on regenerative curative care empowered by a circular-based development engine, 4P-Pharma succeeds in turning existing challenges into actionable therapeutic solutions.
As an experienced leader, what advice would you like to give to aspiring entrepreneurs and enthusiasts who wish to venture into the competitive industry that you are serving?
Be bold and shoot for the moon.
What are the future goals of the organization? How does it envision scaling up its operations and reach in 2022 and beyond?
We are in the process of raising funds. Our upcoming step is to provide more therapeutic solutions for unmet medical needs such as serious infectious respiratory diseases in the next few years.
Give us a few testimonials from your clients or customers and awards or recognition that accurately highlight your company’s position in the market.
At the end of 2021, 4Living Biotech and Sanofi signed a clinical collaboration agreement to demonstrate the potential efficacy of a CXCR4 antagonist for the treatment of acute and chronic complications of viral infections.
Seasoned Entrepreneur in Biotech
With 15+ years of experience, Revital Rattenbach is the founding CEO of 4P-Pharma, clinical-stage Biotech specializing in drug regeneration for treating severe diseases. Under her leadership, 4P-Pharma assembled a unique circular drug development platform that delivered two programs in the clinical stage while nurturing a furnished preclinical pipeline. She signed multiple academic and pharma collaborations worldwide and closed a series of fundraising since 4P-Pharma’s incorporation eight years ago. Prior to her role at 4P-Pharma, Revital was the founding CEO of Pharmaseed Europe, a research organization specializing in early development stage, where she supervised all BD activities, finance, and operations. Prior to Pharmaseed, Revital started her entrepreneurship path by co-founding AdSTEM, a spin-off of Paris IV University developing stem cell activation therapies. She holds a Ph.D. in Biology from the University of René Descartes and an MBA from Sorbonne University.
